HomeAbout usProductsInvestor centreMedia centrePartneringCareers

The Antisoma Board

Antisoma has a highly experienced Board made up of individuals who have held senior positions in international pharmaceutical and biotechnology companies and financial institutions.

Non-Executive Chairman Barry Price, BSc, PhD, FRSC View details
Barry Price, BSc, PhD, FRSC , Non-Executive Chairman  

Barry, 64, was appointed to the Board of Antisoma in April 1997 and became Chairman in February 1998. He is also a Non-Executive Director of Shire plc and Chairman of Summit plc. He has previously held the positions of Director at Chiroscience plc, Celltech Group plc and Pharmagene plc and Director of Primary Production at Glaxochem Ltd.
Close
Chief Executive Officer Glyn Edwards, BSc, MBA, MBE View details
Glyn Edwards, BSc, MBA, MBE, Chief Executive Officer  

Glyn, 52, was appointed Chief Executive Officer in March 1998. He is an Executive Director of Antisoma plc and its subsidiary undertakings Antisoma Research Ltd and Cancer Therapeutics Ltd. Glyn is also an Executive Officer of the subsidiary undertaking Aptamera, Inc. Prior to joining Antisoma he was Director of Business Development at Therapeutic Antibodies.
Close
Chief Operating Officer Ursula Ney, BSc, PhD, MBA View details
Ursula Ney, BSc, PhD, MBA, Chief Operating Officer  

Ursula, 55, was appointed Chief Operating Officer in February 2004. She is an Executive Director of Antisoma plc. Prior to joining Antisoma she was Chief Executive Officer of Charterhouse Therapeutics Ltd. Before her time at Charterhouse she spent 14 years at Celltech, where she was Director of Development and served on the board.
Close
Chief Financial Officer Eric Dodd, MBA View details
Eric Dodd, MBA, Chief Financial Officer  

Eric, 39, joined Antisoma plc as Chief Financial Officer in November 2008 and will shortly be joining the Board as an Executive Director. He was previously Group Finance Director at Morse plc, a consulting IT services and technology company. Before joining Morse in 2005, he held management positions at a number of companies, including GlaxoSmithKline, where he worked in the UK pharmaceuticals business. Mr Dodd qualified as an accountant with Deloitte and holds an MBA from London Business School.
Close
Corporate Development Director Raymond Spencer, BSc, ACA View details
Raymond Spencer, BSc, ACA, Corporate Development Director  

Raymond, 51, was appointed Corporate Development Director in November 2008, having been Chief Financial Officer from 1996 to 2008. He is an Executive Director of Antisoma plc and its subsidiary undertakings Antisoma Research Ltd and Cancer Therapeutics Ltd. Raymond is also an Executive Officer of the subsidiary undertaking Aptamera, Inc. He qualified as a Chartered Accountant with KPMG and, prior to joining Antisoma, was Finance Director at Cambridge Molecular Technologies Ltd.
Close
Non-Executive Director Grahame Cook, MA, FCA View details
Grahame Cook, MA, FCA, Non-Executive Director  

Grahame, 49, was appointed Non-Executive Director in July 1999. He has 17 years of investment banking experience and is a chartered accountant. He was Chief Executive Officer of West LB Panmure until 2003. He was a Managing Director in investment banking at UBS Ltd from 1995 to 1998 and a member of UBS’s Global Investment Banking Management Committee. He was a founder member of the TechMARK Advisory Committee.
Close
Non-Executive Director Michael Pappas, LLB, CA View details
Michael Pappas, LLB, CA, Non-Executive Director  

Michael, 51, was appointed Non-Executive Director of Antisoma Research Ltd in 1993 and of Antisoma plc on formation of the Company in October 1996. He has a degree in law and is a member of the Institute of Chartered Accountants of Scotland. Michael currently serves on the board of a number of companies including Alpheus Capital Management Ltd, Promethean plc and Kudos Independent Financial Services Ltd.
Close
Non-Executive Director Birgit Stattin-Norinder View details
Birgit Stattin-Norinder, Non-Executive Director  

Birgit, 58, was appointed Non-Executive Director in December 2003. She is a trained pharmacist and has held senior executive positions in R&D in Pharmacia & Upjohn Corp. She has also held senior R&D positions at Glaxo Group Research Ltd, Astra Research Centre AB, Pfizer, Inc. and Parke Davis AB. She has been Chief Executive Officer and Chairman of Prolifix Ltd and currently serves on the boards of a number of biotechnology companies including Artimplant AB, deCODE Genetics, Inc. and PhotoCure ASA.
Close
Non-Executive Director Dale Boden, BA View details
Dale Boden, BA, Non-Executive Director  

Dale, 50, was appointed Non-Executive Director in September 2005. He is President of BF Capital Inc., a US private investment firm that focuses on private equity, venture capital investing and real estate development. He also serves on the boards of several US companies. Dale is based in Louisville, Kentucky and was a Director and member of the executive committee of Aptamera, Inc. prior to its acquisition by Antisoma.
Close
Non-Executive Director Michael Lewis View details
Michael Lewis, Non-Executive Director  

Michael, 49, was appointed Non-Executive Director in July 2008. His most recent role was as President for Europe, Middle East and Africa and also Head of Global Marketing for the medical device company Gambro. Before joining Gambro in 2002, he was CEO & Managing Director of Sybron, a specialist dental business based in Switzerland. Mr Lewis has also held senior commercial positions at Boston Scientific International in Paris and Bard International in New Jersey
Close
Delivered by Investis and link to website (opens in a new window)